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objective: This study compared the onset of action of early treatment with clopiogrel and prasugrel in patients with ST elevation myocardial 
infarction undergoing primary percutaneous coronary intervention.
background:  Little is known about the onset of action after a prehospital loading dose of clopidogrel or prasugrel in patients with STEMI.
methods: This double-blind, prospective study randomized 63 patients with STEMI scheduled for primary PCI in the pre-hospital phase or the 
emergency department to 600 mg clopidogrel (n=31) or 60 mg prasugrel (n=32). The primary endpoint was the platetet reactivity index (PRI) 
measured with the VASP assay 2 and 4 hours after intake of the study medication. A lower VASP indicates better platelet inhibition.
Results: The time between symptom onset and administration of the double blind study medication was 125 minutes and between study 
medication and PCI 65 minutes. TIMI 3 flow after PCI was observed in 93 % and 96 % of patients , respectively. The PRI values after 2 hours and after 
4 hours were lower with prasugrel compared to clopidogrel (table). During follow-up until 30 days 1 death occured in the clopi-dogrel group, there 
was no reinfarction, no stroke and two bleeding complications in the prasugrel group.
Clopidogrel (n=31) Prasugrel (n=32) p-value
PRI at baseline 76 % 76 % 0.9
PRI after 2 hours 67 % 50 % 0.08
PRI 4 after hours 55 % 39 % < 0.05
conclusions: The pre-PCI administration of prasugrel in patients with STEMI undergoing primary PCI was associated with a faster and more intense 
inhibition of platelet ADP-receptor inhibition as compared to clopidogrel.
